Molecular farming for food

01Overview and value chain

Markers: [EC: USDA/FDA plant-made protein approval pathway | OECD: Food systems | Regulator: FDA (USA), EFSA (EU)]

Molecular farming for food genetically engineers ordinary food crops to express a single target animal protein directly in the seed or tuber, turning the plant itself into the production bioreactor rather than a fermentation tank or a bioreactor of cultured cells. Moolec Science announced a molecular-farming breakthrough in April 2026, successfully expressing bovine myoglobin — an iron-rich, heme-containing protein — in pea seeds. PoLoPo has filed for USDA approval of its SuperAA platform, which genetically engineers potatoes to produce the egg proteins patatin and ovalbumin. Mozza Foods is targeting a late-2028 launch of soybean-grown casein, pending USDA approval to grow the genetically modified crop and FDA approval to sell the extracted dairy protein — illustrating how the regulatory timeline, not the plant biology, is now the sector’s critical path. Nomad Bioscience already has secured US regulatory approval for one plant-made product, Thaumatin II, a natural super-sweet protein, commercialized through its NAMBAWAN Biotech food-market spin-off.

Key directions of molecular farming for food:

1. Animal-identical protein expression in seed crops (Animal-Identical Protein Expression in Seed Crops): engineering pea, soy or other seed crops to express a specific animal protein (myoglobin, casein) at harvest-ready scale.
2. Tuber-based egg-protein production (Tuber-Based Egg-Protein Production): engineering potatoes to produce named egg proteins (patatin, ovalbumin) as a plant-grown egg-replacement platform.
3. Sweet/functional protein commercialization (Sweet/Functional Protein Commercialization): plant-made specialty proteins (natural sweeteners like thaumatin) reaching market through a dedicated food-market spin-off ahead of the sector’s animal-protein-replacement products.
4. Dual USDA/FDA regulatory gating (Dual USDA/FDA Regulatory Gating): molecular-farming food products need both a GM-crop cultivation approval (USDA) and a food-ingredient sale approval (FDA), a two-step gate distinct from single-agency review in fermentation or cell-culture proteins.

Sectoral value chain

[target protein selection] ──> [crop genetic engineering] ──> [field/greenhouse cultivation] ──> [protein extraction]
                                                                       │
                                                             (dual USDA/FDA
                                                              regulatory review)
                                                                       │
                                                                       ▼
[food ingredient sale] <─── [purification & formulation] <───────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Seed/tuber-specific promoter engineering (Seed/Tuber-Specific Promoter Engineering): genetic constructs that direct target-protein expression specifically to the harvestable seed or tuber tissue.
• Heme/iron-protein plant expression (Heme/Iron-Protein Plant Expression): engineering plants to fold and accumulate iron-containing proteins like myoglobin, historically difficult outside animal or microbial hosts.
• Dual-agency regulatory dossier design (Dual-Agency Regulatory Dossier Design): structuring a single molecular-farming product’s evidence package to satisfy both a crop-cultivation regulator and a food-ingredient regulator.

02US

The US is the site of the sector’s most advanced regulatory filing and a second entrant with a firm public product-launch timeline.

USDA/FDA dual filings, soybean-grown casein timeline, GM-crop cultivation approval

• Mozza Foods: a California-based molecular-farming startup targeting a late-2028 launch of soybean-grown casein, pending USDA approval to grow the GM soybean crop and FDA approval to sell the extracted dairy protein.
• Regulatory sequencing as the critical path: the multi-year gap between scientific proof-of-concept and Mozza’s targeted launch date reflects the dual-agency approval sequence as the sector’s dominant timeline constraint, not the underlying plant science.

03CN

Public information on a dedicated Chinese molecular-farming-for-food originator was not confirmed in this pass; the section stays at the policy level.

no confirmed flagship originator, recombinant-protein reagent supply base, regulatory pathway undefined

• No confirmed flagship originator: a Chinese company engineering food crops specifically to express animal-identical proteins for commercial food sale was not confirmed via live sources in this pass.
• Existing recombinant-protein reagent supply: China has an established recombinant-protein reagent and research-grade supply industry, though this pass found no evidence it has extended into food-grade molecular farming.
• Regulatory pathway undefined: no China-specific dual-agency (crop cultivation plus food-ingredient) approval framework for molecular-farmed food proteins was confirmed in this pass.

04EU

Europe and its adjacent originators (Argentina-rooted, Israel-based, and a German recombinant-protein specialist) supply three of the sector’s most advanced molecular-farming programs.

pea-seed myoglobin breakthrough, potato egg-protein platform, secured US approval for a plant-made sweetener

• Moolec Science: announced a molecular-farming breakthrough in April 2026, successfully expressing bovine myoglobin in pea seeds — a heme-containing, iron-rich protein historically difficult to produce outside an animal host.
• PoLoPo: filed for USDA approval of its SuperAA platform, which genetically engineers potatoes to produce the egg proteins patatin and ovalbumin as a plant-grown egg-replacement ingredient.
• Nomad Bioscience: already holds secured US regulatory approval for Thaumatin II, a natural super-sweet plant-made protein, commercialized through its NAMBAWAN Biotech food-market spin-off, with approvals in other countries pending.

05Leading companies and research institutes

06Tech stack and innovations

The stack turns crop genetic engineering into a food-protein production system.

1. Seed/tuber-specific expression engineering (Seed/Tuber-Specific Expression Engineering):
   • genetic constructs direct protein accumulation specifically to the harvestable seed or tuber rather than the whole plant.
   • case: PoLoPo’s SuperAA platform expresses named egg proteins specifically in potato tubers.
2. Heme-protein plant folding (Heme-Protein Plant Folding):
   • plants are engineered to correctly fold and accumulate iron-containing heme proteins, a historically difficult target outside animal/microbial hosts.
   • case: Moolec Science’s successful bovine myoglobin expression in pea seeds is described as a molecular-farming breakthrough specifically because of this folding challenge.
3. Dual-agency regulatory dossier structuring (Dual-Agency Regulatory Dossier Structuring):
   • a single product’s evidence package is built to satisfy both a crop-cultivation regulator (USDA) and a food-ingredient regulator (FDA) in sequence.
   • case: Mozza Foods’ soybean-grown casein timeline is explicitly paced by this two-step approval sequence rather than by production scale-up.

07Value chains and production pipelines

Industrial pipeline of a molecular-farmed food protein (dual USDA/FDA review)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Target protein selection│ ───> │ 2. Crop genetic engineering│
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Protein extraction     │ <─── │ 3. Field/greenhouse cultivation│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Dual regulatory review │ ───> │ 6. Food ingredient launch │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Target protein selection

An animal-identical protein sequence (myoglobin, ovalbumin, casein, thaumatin) is selected for plant expression.

Stage 2: Crop genetic engineering

The expression construct, with a seed- or tuber-specific promoter, is inserted into the host crop’s genome.

Stage 3: Field/greenhouse cultivation

The transgenic crop is grown to harvest under regulated field or greenhouse conditions.

Stage 4: Protein extraction

The target protein is extracted and purified from the harvested seed or tuber biomass.

Stage 5: Dual regulatory review

The product clears both a crop-cultivation approval (USDA) and a food-ingredient sale approval (FDA), or the EFSA equivalent in the EU.

Stage 6: Food ingredient launch

The cleared ingredient enters food manufacturing; Nomad Bioscience’s Thaumatin II has already reached this stage in the US, while Mozza Foods and PoLoPo are still working through Stage 5.